Bausch + Lomb (BLCO) Stock Forecast, Price Target & Predictions
BLCO Stock Forecast
Bausch + Lomb stock forecast is as follows: an average price target of $22.29 (represents a 12.18% upside from BLCO’s last price of $19.87) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
BLCO Price Target
The average price target for Bausch + Lomb (BLCO) is $22.29 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $18.00. This represents a potential 12.18% upside from BLCO's last price of $19.87.
BLCO Analyst Ratings
According to 9 Wall Street analysts, Bausch + Lomb's rating consensus is 'Buy'. The analyst rating breakdown for BLCO stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bausch + Lomb Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Yi Chen | H.C. Wainwright | $23.00 | $20.44 | 12.52% | 15.75% |
| Oct 22, 2024 | Doug Miehm | RBC Capital | $23.00 | $20.68 | 11.22% | 15.75% |
| Oct 15, 2024 | Larry Biegelsen | Wells Fargo | $23.00 | $20.87 | 10.21% | 15.75% |
| Oct 15, 2024 | Vijay Kumar | Evercore ISI | $25.00 | $20.87 | 19.79% | 25.82% |
| Sep 23, 2024 | Tom Stephan | Stifel Nicolaus | $19.00 | $19.85 | -4.28% | -4.38% |
| Sep 19, 2024 | Zachary Weiner | Jefferies | $25.00 | $20.05 | 24.66% | 25.82% |
| Jul 22, 2024 | Doug Miehm | RBC Capital | $20.00 | $16.98 | 17.79% | 0.65% |
| May 06, 2024 | Patrick Wood | Morgan Stanley | $18.00 | $13.60 | 32.35% | -9.41% |
| May 08, 2023 | Yi Chen | H.C. Wainwright | $19.00 | $18.16 | 4.65% | -4.38% |
| Jul 28, 2022 | Vijay Kumar | Evercore ISI | $21.00 | $14.86 | 41.32% | 5.69% |
The latest Bausch + Lomb stock forecast, released on Oct 31, 2024 by Yi Chen from H.C. Wainwright, set a price target of $23.00, which represents a 12.52% increase from the stock price at the time of the forecast ($20.44), and a 15.75% increase from BLCO last price ($19.87).
Bausch + Lomb Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 6 | 8 |
| Avg Price Target | $23.50 | $23.00 | $22.00 |
| Last Closing Price | $19.87 | $19.87 | $19.87 |
| Upside/Downside | 18.27% | 15.75% | 10.72% |
In the current month, the average price target of Bausch + Lomb stock is $23.50, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 18.27% increase as opposed to Bausch + Lomb's last price of $19.87. This month's average price target is up 2.17% compared to last quarter, and up 6.82% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 22, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 15, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Oct 15, 2024 | Evercore ISI | Positive | Outperform | Upgrade |
| Oct 01, 2024 | Evercore ISI | Positive | Positive | Hold |
| Sep 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 19, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 22, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 10, 2024 | Raymond James | - | Outperform | Initialise |
Bausch + Lomb's last stock rating was published by Citigroup on Oct 31, 2024. The company gave BLCO a "Buy" rating, the same as its previous rate.
Bausch + Lomb Financial Forecast
Bausch + Lomb Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.01B | $1.03B | $931.00M | $996.00M | $942.00M | $941.00M | $889.00M |
| Avg Forecast | $1.34B | $1.26B | $1.29B | $1.17B | $1.26B | $1.17B | $1.17B | $1.06B | $1.11B | $990.68M | $963.69M | $895.80M | $966.92M | $949.72M | $908.52M | $889.00M |
| High Forecast | $1.36B | $1.29B | $1.31B | $1.23B | $1.28B | $1.17B | $1.17B | $1.06B | $1.13B | $1.02B | $983.26M | $914.00M | $986.56M | $949.72M | $908.52M | $889.00M |
| Low Forecast | $1.33B | $1.25B | $1.27B | $1.15B | $1.24B | $1.17B | $1.17B | $1.06B | $1.10B | $974.14M | $954.62M | $887.37M | $957.83M | $949.72M | $908.52M | $889.00M |
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.07% | 1.04% | 1.03% | 0.99% | 1.04% | 1.00% |
Bausch + Lomb's average Quarter revenue forecast for Dec 23 based on 6 analysts is $1.11B, with a low forecast of $1.10B, and a high forecast of $1.13B. BLCO's average Quarter revenue forecast represents a 9.85% increase compared to the company's last Quarter revenue of $1.01B (Sep 23).
Bausch + Lomb EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $40.00M | $43.00M | $58.00M | $110.00M | $147.00M | $154.00M | $151.00M |
| Avg Forecast | $256.72M | $242.57M | $246.68M | $223.80M | $242.12M | $225.10M | $224.67M | $203.99M | $212.29M | $190.11M | $184.93M | $171.91M | $185.55M | $182.25M | $104.59M | $170.60M |
| High Forecast | $261.94M | $247.50M | $251.70M | $235.28M | $245.93M | $225.29M | $224.68M | $203.99M | $216.60M | $195.16M | $188.69M | $175.40M | $189.32M | $182.25M | $125.50M | $170.60M |
| Low Forecast | $254.31M | $240.29M | $244.36M | $219.98M | $238.30M | $224.91M | $224.67M | $203.99M | $210.29M | $186.94M | $183.19M | $170.29M | $183.81M | $182.25M | $83.67M | $170.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.21% | 0.23% | 0.34% | 0.59% | 0.81% | 1.47% | 0.89% |
6 analysts predict BLCO's average Quarter EBITDA for Dec 23 to be $212.29M, with a high of $216.60M and a low of $210.29M. This is 430.72% upper than Bausch + Lomb's previous annual EBITDA (Sep 23) of $40.00M.
Bausch + Lomb Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-84.00M | $-32.00M | $-88.00M | - | $-15.00M | $7.00M | $20.00M |
| Avg Forecast | $97.00M | $80.60M | $76.41M | $51.40M | $86.35M | $55.65M | $45.47M | $24.90M | $59.89M | $66.56M | $51.55M | $47.91M | $78.91M | $84.02M | $3.13M | $82.32M |
| High Forecast | $99.56M | $82.73M | $78.42M | $71.39M | $97.14M | $55.88M | $45.56M | $24.96M | $73.98M | $81.92M | $52.91M | $49.18M | $80.99M | $84.02M | $3.76M | $82.32M |
| Low Forecast | $95.81M | $79.62M | $75.47M | $34.26M | $79.15M | $55.43M | $45.38M | $24.83M | $42.27M | $40.96M | $50.92M | $47.33M | $77.94M | $84.02M | $2.51M | $82.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.26% | -0.62% | -1.84% | - | -0.18% | 2.24% | 0.24% |
Bausch + Lomb's average Quarter net income forecast for Sep 22 is $84.02M, with a range of $84.02M to $84.02M. BLCO's average Quarter net income forecast represents a 1100.24% increase compared to the company's last Quarter net income of $7.00M (Jun 22).
Bausch + Lomb SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $418.00M | $417.00M | $418.00M | $386.00M | $381.00M | $368.00M | $343.00M |
| Avg Forecast | $511.81M | $483.60M | $491.80M | $446.19M | $482.70M | $448.77M | $447.92M | $406.68M | $423.23M | $379.02M | $368.69M | $342.72M | $369.93M | $363.35M | $230.46M | $340.12M |
| High Forecast | $522.21M | $493.42M | $501.79M | $469.07M | $490.30M | $449.15M | $447.92M | $406.68M | $431.83M | $389.09M | $376.18M | $349.68M | $377.45M | $363.35M | $276.56M | $340.12M |
| Low Forecast | $507.00M | $479.05M | $487.18M | $438.56M | $475.09M | $448.38M | $447.92M | $406.68M | $419.25M | $372.69M | $365.22M | $339.50M | $366.45M | $363.35M | $184.37M | $340.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.10% | 1.13% | 1.22% | 1.04% | 1.05% | 1.60% | 1.01% |
Bausch + Lomb's average Quarter SG&A projection for Dec 23 is $423.23M, based on 6 Wall Street analysts, with a range of $419.25M to $431.83M. The forecast indicates a 1.25% rise compared to BLCO last annual SG&A of $418.00M (Sep 23).
Bausch + Lomb EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.24 | $-0.09 | $-0.25 | - | $-0.04 | $0.02 | $0.06 |
| Avg Forecast | $0.27 | $0.23 | $0.22 | $0.15 | $0.24 | $0.16 | $0.13 | $0.07 | $0.17 | $0.19 | $0.15 | $0.14 | $0.22 | $0.24 | $0.20 | $0.23 |
| High Forecast | $0.28 | $0.23 | $0.22 | $0.20 | $0.27 | $0.16 | $0.13 | $0.07 | $0.21 | $0.23 | $0.15 | $0.14 | $0.23 | $0.24 | $0.20 | $0.23 |
| Low Forecast | $0.27 | $0.22 | $0.21 | $0.10 | $0.22 | $0.16 | $0.13 | $0.07 | $0.12 | $0.12 | $0.14 | $0.13 | $0.22 | $0.24 | $0.20 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.28% | -0.63% | -1.85% | - | -0.18% | 0.10% | 0.24% |
According to 3 Wall Street analysts, Bausch + Lomb's projected average Quarter EPS for Sep 22 is $0.24, with a low estimate of $0.24 and a high estimate of $0.24. This represents a 1094.10% increase compared to BLCO previous annual EPS of $0.02 (Jun 22).
Bausch + Lomb Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.62 | $7.90 | 201.53% | Buy |
| COO | Cooper Companies | $104.86 | $298.00 | 184.19% | Buy |
| ANGO | AngioDynamics | $6.74 | $15.00 | 122.55% | Buy |
| ATRC | AtriCure | $33.66 | $49.57 | 47.27% | Buy |
| TFX | Teleflex | $207.33 | $304.82 | 47.02% | Buy |
| HAE | Haemonetics | $73.53 | $104.33 | 41.89% | Buy |
| BDX | Becton, Dickinson and Company | $234.33 | $283.27 | 20.89% | Buy |
| BLCO | Bausch + Lomb | $19.87 | $22.29 | 12.18% | Buy |
| WST | West Pharmaceutical Services | $314.77 | $345.33 | 9.71% | Buy |
| ALC | Alcon | $92.17 | $93.89 | 1.87% | Buy |
| ICUI | ICU Medical | $172.00 | $172.00 | - | Buy |
| HOLX | Hologic | $83.72 | $80.43 | -3.93% | Buy |
| RMD | ResMed | $243.61 | $219.13 | -10.05% | Hold |
| ATR | AptarGroup | $168.26 | $138.00 | -17.98% | Buy |
BLCO Forecast FAQ
Is Bausch + Lomb a good buy?
Yes, according to 9 Wall Street analysts, Bausch + Lomb (BLCO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 88.89% of BLCO's total ratings.
What is BLCO's price target?
Bausch + Lomb (BLCO) average price target is $22.29 with a range of $18 to $25, implying a 12.18% from its last price of $19.87. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bausch + Lomb stock go up soon?
According to Wall Street analysts' prediction for BLCO stock, the company can go up by 12.18% (from the last price of $19.87 to the average price target of $22.29), up by 25.82% based on the highest stock price target, and down by -9.41% based on the lowest stock price target.
Can Bausch + Lomb stock reach $30?
BLCO's average twelve months analyst stock price target of $22.29 does not support the claim that Bausch + Lomb can reach $30 in the near future.
What is Bausch + Lomb's current price target trend?
4 Wall Street analysts forecast a $23.5 price target for Bausch + Lomb (BLCO) this month, up 18.27% from its last price of $19.87. Compared to the last 3 and 12 months, the average price target increased by 15.75% and increased by 10.72%, respectively.
What are Bausch + Lomb's analysts' financial forecasts?
Bausch + Lomb's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.67B (high $4.69B, low $4.65B), average EBITDA is $895.88M (high $899.88M, low $891.87M), average net income is $212.37M (high $223.54M, low $204.8M), average SG&A $1.79B (high $1.79B, low $1.78B), and average EPS is $0.6 (high $0.632, low $0.579). BLCO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.05B (high $5.19B, low $5B), average EBITDA is $969.78M (high $996.41M, low $958.93M), average net income is $305.41M (high $332.1M, low $285.17M), average SG&A $1.93B (high $1.99B, low $1.91B), and average EPS is $0.863 (high $0.938, low $0.806).
Did the BLCO's actual financial results beat the analysts' financial forecasts?
Based on Bausch + Lomb's last annual report (Dec 2022), the company's revenue was $3.77B, beating the average analysts forecast of $3.71B by 1.45%. Apple's EBITDA was $457M, missing the average prediction of $642.99M by -28.93%. The company's net income was $15M, missing the average estimation of $248.38M by -93.96%. Apple's SG&A was $1.48B, beating the average forecast of $1.3B by 13.36%. Lastly, the company's EPS was $0.0429, missing the average prediction of $0.892 by -95.19%. In terms of the last quarterly report (Sep 2023), Bausch + Lomb's revenue was $1.01B, beating the average analysts' forecast of $990.68M by 1.65%. The company's EBITDA was $40M, missing the average prediction of $190.11M by -78.96%. Bausch + Lomb's net income was $-84M, missing the average estimation of $66.56M by -226.20%. The company's SG&A was $418M, beating the average forecast of $379.02M by 10.28%. Lastly, the company's EPS was $-0.24, missing the average prediction of $0.188 by -227.61%